A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge

Vaccine

Volumn 17, Issue 9-10, 1999, Pages 1100-1108

  Tao, T ^a   Skiadopoulos, M H ^a   Durbin, A P ^a   Davoodi, F ^a   Collins, P L ^a   Murphy, B R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE;

ANTIBODY RESPONSE; ARTICLE; HUMAN; HUMAN CELL; IMMUNOGENICITY; INFECTION RESISTANCE; INFLUENZA; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; VACCINE PRODUCTION;

ANIMALS; CELL LINE; CRICETINAE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNIZATION; MESOCRICETUS; PARAINFLUENZA VIRUS 1, HUMAN; PARAINFLUENZA VIRUS 3, HUMAN; RECEPTORS, VIRUS; RESPIRATORY SYSTEM; SURFACE PROPERTIES; TEMPERATURE; VACCINES, ATTENUATED; VIRAL FUSION PROTEINS; VIRUS REPLICATION;

EID: 0033525729     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00327-2     Document Type: Article

References (38)

1. Murphy B.R., Prince G.A., Collins P.L.et al. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res. 11:1988;1-15.
2. Karron R.A., Wright P.F., Newman F.K.et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis. 172:1995;1445-1450.
3. Karron R.A., Wright P.F., Hall S.L.et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis. 171:1995;1107-1114.
4. Karron R.A., Makhene M., Gay K., Wilson M.H., Clements M.L., Murphy B.R. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants. Pediatr Infect Dis J. 15:1996;650-654.
5. Belshe R.B., Hissom F.K. Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J Med Virol. 10:1982;235-242.
6. Belshe R.B., Van Voris L.P., Mufson M.A., Buynak E.B., McLean A.A., Hilleman M.A. Comparison of enzyme-linked immunosorbent assay and neutralization techniques for measurement of antibody to respiratory syncytial virus: implications for parenteral immunization with live virus vaccine. Infect Immun. 37:1982;160-165.
7. Crookshanks F.K., Belshe R.B. Evaluation of cold-adapted and temperature-sensitive mutants of parainfluenza virus type 3 in weanling hamsters. J Med Virol. 13:1984;243-249.
8. Clements M.L., Belshe R.B., King J.et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol. 29:1991;1175-1182.
9. Hall S.L., Stokes A., Tierney E.L.et al. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res. 22:1992;173-184.
10. Collins PL, Chanock RM, McIntosh K. Parainfluenza viruses. In: Fields BN, Knipe DM, Howley PM et al., editors. Fields virology, vol. 1. 3rd ed. Philadelphia: Lippincott-Raven Publishers, 1996. p. 1205-43.
11. Galinski M.S., Troy R.M., Banerjee A.K. RNA editing in the phosphoprotein gene of the human parainfluenza virus type 3. Virology. 186:1992;543-550.
12. Cook K.M., Chanock R.M. In vivo antigenic studies of parainfluenza viruses. Am J Hyg. 77:1963;150-159.
13. Ray R., Matsuoka Y., Burnett T.L., Glaze B.J., Compans R.W. Human parainfluenza virus induces a type-specific protective immune response. J Infect Dis. 162:1990;746-749.
14. Durbin A.P., Hall S.L., Siew J.W., Whitehead S.S., Collins P.L., Murphy B.R. Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology. 235:1997;323-332.
15. Hoffman M.A., Banerjee A.K. An infectious clone of human parainfluenza virus type 3. J Virol. 71:1997;4272-4277.
16. Skiadopoulos M.H., Durbin A.P., Tatem J.M.et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J Virol. 72:1998;1762-1768.
17. Tao T., Durbin A.P., Whitehead S.S., Davoodi F., Collins P.L., Murphy B.R. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoprotein have been replaced by those of PIV type 1. J Virol. 72:1998;2955-2961.
18. Murphy B.R., Richman D.D., Chalhub E.G., Uhlendorf C.P., Baron S., Chanock R.M. Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus. Infect Immun. 12:1975;62-68.
19. Wyatt L.S., Moss B., Rozenblatt S. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells. Virology. 210:1995;202-205.
20. Durbin A.P., Siew J.W., Murphy B.R., Collins P.L. Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six. Virology. 234:1997;74-83.
21. Stokes A., Tierney E.L., Sarris C.M., Murphy B.R., Hall S.L. The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses (cp12 and cp45) derived from the JS strain of human parainfluenza virus type 3 (PIV3). Virus Res. 30:1993;43-52.
22. Kast W.M., Roux L., Curren J.et al. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T-lymphocytes with a free synthetic peptide. Proc Natl Acad Sci USA. 88:1991;2283-2287.
23. Orvell C., Grandien M. The effects of monoclonal antibodies on biologic activities of structural proteins of Sendai virus. J Immunol. 129:1982;2779-2787.
24. Paterson R.G., Lamb R.A., Moss B., Murphy B.R. Comparison of the relative roles of the F and HN surface glycoproteins of the paramyxovirus simian virus 5 in inducing protective immunity. J Virol. 61:1987;1972-1977.
25. Sakaguchi T., Takao S., Kiyotani K., Fujii Y., Nakayama T., Yoshida T. Expression of the HN, F, NP and M proteins of Sendai virus by recombinant vaccinia viruses and their contribution to protective immunity against Sendai virus infections in mice. J Gen Virol. 74:1993;479-484.
26. Spriggs M.K., Murphy B.R., Prince G.A., Olmsted R.A., Collins P.L. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol. 61:1987;3416-3423.
27. Bukreyev A., Whitehead S.S., Murphy B.R., Collins P.L. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol. 71:1997;8973-8982.
28. Crookshanks-Newman F.K., Belshe R.B. Protection of weanling hamsters from experimental infection with wild-type parainfluenza virus type 3 (para 3) by cold-adapted mutants of para 3. J Med Virol. 18:1986;131-137.
29. Crowe J.E. Jr., Bui P.T., Firestone C.Y.et al. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable and immunogenic in rodents and nonhuman primates. J Infect Dis. 173:1996;829-839.
30. Ambrose M.W., Wyde P.R., Ewasyshyn M.et al. Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats. Vaccine. 9:1991;505-511.
31. Ewasyshyn M., Caplan B., Bonneau A.M.et al. Comparative analysis of the immunostimulatory properties of different adjuvants on the immunogenicity of a prototype parainfluenza virus type 3 subunit vaccine. Vaccine. 10:1992;412-420.
32. Hall S.L., Murphy B.R., van Wyke Coelingh K.L. Protection of cotton rats by immunization with the human parainfluenza virus type 3 fusion (F) glycoprotein expressed on the surface of insect cells infected with a recombinant baculovirus. Vaccine. 9:1991;659-667.
33. van Wyke Coelingh K.L., Murphy B.R., Collins P.L., Lebacq-Verheyden A.M., Battey J.F. Expression of biologically active and antigenically authentic parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein by a recombinant baculovirus. Virology. 160:1987;465-472.
34. Thomson S.A., Elliott S.L., Sherritt M.A.et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T-cell epitopes. J Immunol. 157:1996;822-826.
35. Epstein S., Lo C., Misplon J., Bennink J. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol. 160:1998;322-327.
36. Chanock R.M., Wong D.C., Huebner R.J., Bell J.A. Serologic response of individuals infected with para influenza viruses. Am J Publ Health. 50:1960;1858-1865.
37. Reed G., Jewett P.H., Thompson J., Tollefson S., Wright P.F. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J Infect Dis. 175:1997;807-813.
38. Cook K.M., Andrews B.E., Fox H.H., Turner H.C., James W.D., Chanock R.M. Antigenic relationships among the 'newer' myxoviruses (parainfluenza). Am J Hyg. 69:1959;250-264.